

# Carlo Leonetti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4084182/publications.pdf>

Version: 2024-02-01

116  
papers

5,378  
citations

70961

41  
h-index

95083

68  
g-index

128  
all docs

128  
docs citations

128  
times ranked

7779  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 927-931.   | 0.8 | 274       |
| 2  | Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. <i>Journal of Clinical Investigation</i> , 2007, 117, 3236-3247.  | 3.9 | 212       |
| 3  | Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. <i>Clinical Cancer Research</i> , 2003, 9, 5370-9. | 3.2 | 160       |
| 4  | Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway. <i>Nucleic Acids Research</i> , 2009, 37, 5353-5364.   | 6.5 | 152       |
| 5  | Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 57.  | 3.5 | 140       |
| 6  | Biological Activity of the G-Quadruplex Ligand RHPS4 (3,11-Difluoro-6,8,13-trimethyl-8H-quinolo[4,3,2-kl]acridinium methosulfate) Is Associated with Telomere Capping Alteration. <i>Molecular Pharmacology</i> , 2004, 66, 1138-1146.      | 1.0 | 134       |
| 7  | Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. <i>European Journal of Cancer</i> , 2007, 43, 2124-2133.  | 1.3 | 128       |
| 8  | Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. <i>FASEB Journal</i> , 1997, 11, 947-953.   | 0.2 | 126       |
| 9  | Antibody-drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin. <i>Nanoscale</i> , 2013, 5, 12278.  | 2.8 | 119       |
| 10 | Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. <i>Cell Cycle</i> , 2011, 10, 1679-1689.  | 1.3 | 116       |
| 11 | Antitumor Effect of c-myc Antisense Phosphorothioate Oligodeoxynucleotides on Human Melanoma Cells In Vitro and in Mice. <i>Journal of the National Cancer Institute</i> , 1996, 88, 419-429.   | 3.0 | 115       |
| 12 | Patient-derived xenografts: a relevant preclinical model for drug development. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 189.   | 3.5 | 109       |
| 13 | Che-1 phosphorylation by ATM/ATR and Chk2 kinases activates p53 transcription and the G2/M checkpoint. <i>Cancer Cell</i> , 2006, 10, 473-486.  | 7.7 | 106       |
| 14 | PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy. <i>Oncogene</i> , 2010, 29, 6280-6293.   | 2.6 | 103       |
| 15 | TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. <i>Nature Cell Biology</i> , 2013, 15, 818-828.   | 4.6 | 99        |
| 16 | Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 955-964.                             | 1.7 | 98        |
| 17 | Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. <i>FASEB Journal</i> , 2006, 20, 1709-1711.                                  | 0.2 | 97        |
| 18 | Zinc Downregulates HIF-1 $\alpha$ and Inhibits Its Activity in Tumor Cells In Vitro and In Vivo. <i>PLoS ONE</i> , 2010, 5, e15048.   | 1.1 | 96        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Cathepsin B inhibition interferes with metastatic potential of human melanoma: an in vitro and in vivo study. <i>Molecular Cancer</i> , 2010, 9, 207.  | 7.9 | 91        |
| 20 | New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. <i>Biotechnology Advances</i> , 2012, 30, 302-309.   | 6.0 | 84        |
| 21 | Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. <i>Blood</i> , 2002, 99, 2241-2244.  | 0.6 | 83        |
| 22 | G-Quadruplex Ligand RHPS4 Potentiates the Antitumor Activity of Camptothecins in Preclinical Models of Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 7284-7291.  | 3.2 | 82        |
| 23 | The future of antisense therapy: combination with anticancer treatments. <i>Oncogene</i> , 2003, 22, 6579-6588.  | 2.6 | 79        |
| 24 | Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. <i>International Journal of Pharmaceutics</i> , 2011, 403, 292-297.   | 2.6 | 79        |
| 25 | Reversible Dysfunction of Wild-Type p53 following Homeodomain-Interacting Protein Kinase-2 Knockdown. <i>Cancer Research</i> , 2008, 68, 3707-3714.  | 0.4 | 78        |
| 26 | Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. <i>Oncogene</i> , 2011, 30, 3813-3820.   | 2.6 | 76        |
| 27 | Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. <i>Cell Death and Disease</i> , 2018, 9, 996.   | 2.7 | 75        |
| 28 | ?-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. <i>International Journal of Cancer</i> , 2003, 104, 243-250.   | 2.3 | 72        |
| 29 | Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. <i>Oncotarget</i> , 2014, 5, 10446-10459.  | 0.8 | 71        |
| 30 | A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 72.  | 3.5 | 68        |
| 31 | TRF2 inhibition triggers apoptosis and reduces tumorigenicity of human melanoma cells. <i>European Journal of Cancer</i> , 2006, 42, 1881-1888.  | 1.3 | 62        |
| 32 | Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. <i>Cancer Gene Therapy</i> , 2001, 8, 459-468.   | 2.2 | 60        |
| 33 | R115777 (Zarnestra®)/Zoledronic acid (Zometa®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. <i>Journal of Cellular Physiology</i> , 2007, 211, 533-543. | 2.0 | 57        |
| 34 | Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. <i>Cancer Biology and Therapy</i> , 2012, 13, 1491-1500.   | 1.5 | 57        |
| 35 | Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells. <i>Oncotarget</i> , 2015, 6, 2779-2793.  | 0.8 | 56        |
| 36 | A New Avenue toward Androgen Receptor Pan-antagonists: C2 Sterically Hindered Substitution of Hydroxy-propanamides. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7263-7279.   | 2.9 | 53        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2. <i>Cell Death and Differentiation</i> , 2017, 24, 889-902.  | 5.0 | 53        |
| 38 | N-Cyclic Bay-Substituted Perylene G-Quadruplex Ligands Have Selective Antiproliferative Effects on Cancer Cells and Induce Telomere Damage. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1140-1156.   | 2.9 | 51        |
| 39 | Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein <scp>TRF</scp> 2. <i>EMBO Journal</i> , 2019, 38, .   | 3.5 | 49        |
| 40 | Sensitivity to DNA cross-linking chemotherapeutic agents in mismatch repair-defective cells in vitro and in xenografts. , 2000, 85, 590-596.   |     | 48        |
| 41 | Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis. <i>Nucleic Acids Research</i> , 2014, 42, 2945-2957.   | 6.5 | 45        |
| 42 | Transferrin-Targeted Nanoparticles Containing Zoledronic Acid as a Potential Tool to Inhibit Glioblastoma Growth. <i>Journal of Biomedical Nanotechnology</i> , 2016, 12, 811-830.   | 0.5 | 45        |
| 43 | Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 919-926.  | 1.9 | 43        |
| 44 | Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice. <i>International Journal of Cancer</i> , 2004, 110, 125-133. | 2.3 | 42        |
| 45 | Functional role of $\alpha 4 \beta 1$ and $\alpha 5 \beta 1$ integrin fibronectin receptors expressed on adriamycin-resistant MCF-7 human mammary carcinoma cells. , 1997, 72, 133-141.  |     | 41        |
| 46 | Intragenic G-quadruplex structure formed in the human CD133 and its biological and translational relevance. <i>Nucleic Acids Research</i> , 2016, 44, 1579-1590.   | 6.5 | 40        |
| 47 | Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitizer of malignant melanoma for temozolomide. <i>European Journal of Cancer</i> , 2005, 41, 2948-2957.  | 1.3 | 37        |
| 48 | Enhanced Anti-Tumor Effects with Microencapsulated c-myc Antisense Oligonucleotide. <i>Oligonucleotides</i> , 1999, 9, 451-458.  | 4.4 | 35        |
| 49 | FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. <i>Journal of Hepatology</i> , 2021, 75, 351-362.  | 1.8 | 35        |
| 50 | Telomerase as a new target for the treatment of hormone-refractory prostate cancer. <i>Endocrine-Related Cancer</i> , 2004, 11, 407-421.   | 1.6 | 34        |
| 51 | TRF2 positively regulates SULF2 expression increasing VEGF-A release and activity in tumor microenvironment. <i>Nucleic Acids Research</i> , 2019, 47, 3365-3382.  | 6.5 | 34        |
| 52 | In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. <i>Journal of Translational Medicine</i> , 2005, 3, 7.  | 1.8 | 33        |
| 53 | Targeting Different Signaling Pathways with Antisense Oligonucleotides Combination for Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2007, 13, 463-470.   | 0.9 | 33        |
| 54 | DNA Damage Persistence as Determinant of Tumor Sensitivity to the Combination of Topo I Inhibitors and Telomere-Targeting Agents. <i>Clinical Cancer Research</i> , 2011, 17, 2227-2236.   | 3.2 | 33        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Aromatic Core Extension in the Series of Nâ€Cyclic Bayâ€Substituted Perylene Gâ€Quadruplex Ligands: Increased Telomere Damage, Antitumor Activity, and Strong Selectivity for Neoplastic over Healthy Cells. <i>ChemMedChem</i> , 2012, 7, 2144-2154. | 1.6 | 33        |
| 56 | Che-1 activates XIAP expression in response to DNA damage. <i>Cell Death and Differentiation</i> , 2008, 15, 515-520.   | 5.0 | 32        |
| 57 | Identification of novel RHPS4-derivative ligands with improved toxicological profiles and telomere-targeting activities. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 81.  | 3.5 | 32        |
| 58 | Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 279.                                     | 3.5 | 32        |
| 59 | Drug-releasing mesenchymal cells strongly suppress B16 lung metastasis in a syngeneic murine model. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 82.   | 3.5 | 30        |
| 60 | Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 189.   | 3.5 | 30        |
| 61 | Adipose-derived stem cell-mediated paclitaxel delivery inhibits breast cancer growth. <i>PLoS ONE</i> , 2018, 13, e0203426.   | 1.1 | 30        |
| 62 | Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones. <i>Oncogene</i> , 2002, 21, 3011-3019.   | 2.6 | 29        |
| 63 | Lonidamine Causes Inhibition of Angiogenesis-Related Endothelial Cell Functions. <i>Neoplasia</i> , 2004, 6, 513-522.   | 2.3 | 29        |
| 64 | A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. <i>Biochemical Pharmacology</i> , 2015, 95, 16-27.  | 2.0 | 29        |
| 65 | Antitumor Efficacy of bcl-2 and c-myc Antisense Oligonucleotides in Combination with Cisplatin in Human Melanoma Xenografts: Relevance of the Administration Sequence. <i>Clinical Cancer Research</i> , 2005, 11, 1990-1998.                         | 3.2 | 28        |
| 66 | NCX 4040, an NO-donating acetylsalicylic acid derivative: Efficacy and mechanisms of action in cancer cells. <i>Nitric Oxide - Biology and Chemistry</i> , 2008, 19, 225-236.   | 1.2 | 27        |
| 67 | Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2541-2551.  | 1.9 | 27        |
| 68 | HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma. <i>Hepatology</i> , 2019, 69, 131-142.  | 3.6 | 27        |
| 69 | Chlorambucil targets <sc>BRCA</sc> 1/2â€deficient tumours and counteracts <sc>PARP</sc> inhibitor resistance. <i>EMBO Molecular Medicine</i> , 2019, 11, e9982.   | 3.3 | 26        |
| 70 | In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors. <i>International Journal of Cancer</i> , 2004, 110, 767-774.  | 2.3 | 25        |
| 71 | Down-regulation of the Lamin A/C in neuroblastoma triggers the expansion of tumor initiating cells. <i>Oncotarget</i> , 2015, 6, 32821-32840.   | 0.8 | 23        |
| 72 | On and off-target effects of telomere uncapping G-quadruplex selective ligands based on pentacyclic acridinium salts. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 68.   | 3.5 | 22        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line. <i>European Journal of Cancer</i> , 2001, 37, 2247-2256.  | 1.3 | 21        |
| 74 | Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. <i>Prostate</i> , 2007, 67, 1475-1485.  | 1.2 | 21        |
| 75 | Perylene and coronene derivatives binding to G-rich promoter oncogene sequences efficiently reduce their expression in cancer cells. <i>Biochimie</i> , 2016, 125, 223-231.   | 1.3 | 21        |
| 76 | Cell communication and signaling: how to turn bad language into positive one. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 128.  | 3.5 | 21        |
| 77 | Effect of Small Molecules Modulating Androgen Receptor (SARMs) in Human Prostate Cancer Models. <i>PLoS ONE</i> , 2013, 8, e62657.  | 1.1 | 20        |
| 78 | Hybrid lipid self-assembling nanoparticles for brain delivery of microRNA. <i>International Journal of Pharmaceutics</i> , 2020, 588, 119693.   | 2.6 | 19        |
| 79 | Temozolomide reduces the metastatic potential of lewis lung carcinoma (3LL) in mice: Role of $\alpha$ -6 integrin phosphorylation. <i>European Journal of Cancer</i> , 1995, 31, 746-754.   | 1.3 | 18        |
| 80 | Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent. <i>Current Cancer Drug Targets</i> , 2010, 10, 368-383. | 0.8 | 18        |
| 81 | EMICORON: A multi-targeting G4 ligand with a promising preclinical profile. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 1362-1370.  | 1.1 | 17        |
| 82 | Ras inhibition amplifies cisplatin sensitivity of human glioblastoma. <i>Biochemical and Biophysical Research Communications</i> , 2004, 320, 493-500.  | 1.0 | 16        |
| 83 | Potential of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells. <i>Cancer Biology and Therapy</i> , 2005, 4, 866-871.  | 1.5 | 15        |
| 84 | A basal level of DNA damage and telomere deprotection increases the sensitivity of cancer cells to G-quadruplex interactive compounds. <i>Nucleic Acids Research</i> , 2015, 43, 1759-1769.   | 6.5 | 15        |
| 85 | Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 364.   | 3.5 | 15        |
| 86 | Bcl-2 overexpression decreases BCNU sensitivity of a human glioblastoma line through enhancement of catalase activity. <i>Journal of Cellular Biochemistry</i> , 2001, 83, 473-483.   | 1.2 | 14        |
| 87 | TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 111.   | 3.5 | 14        |
| 88 | In Vitro and In Vivo Antitumor Efficacy of Docetaxel and Sorafenib Combination in Human Pancreatic Cancer Cells. <i>Current Cancer Drug Targets</i> , 2010, 10, 600-610.  | 0.8 | 13        |
| 89 | Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours. <i>EMBO Molecular Medicine</i> , 2022, 14, e14501.  | 3.3 | 13        |
| 90 | Different effects of sequential combinations of N-methylformamide with 5-fluorouracil on human colon carcinoma cells growing in nude mice. <i>Journal of Cancer Research and Clinical Oncology</i> , 1991, 117, 351-358.                                      | 1.2 | 11        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Increased TGF $\beta$ 2 Type II Receptor Expression Suppresses the Malignant Phenotype and Induces Differentiation of Human Neuroblastoma Cells. <i>Experimental Cell Research</i> , 2000, 255, 77-85.            | 1.2 | 11        |
| 92  | Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft. <i>Journal of Translational Medicine</i> , 2011, 9, 125.                              | 1.8 | 11        |
| 93  | Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan. <i>International Journal of Oncology</i> , 2013, 43, 210-218.                                    | 1.4 | 10        |
| 94  | Chitosan-Based Polyelectrolyte Complexes for Doxorubicin and Zoledronic Acid Combined Therapy to Overcome Multidrug Resistance. <i>Pharmaceutics</i> , 2018, 10, 180.   | 2.0 | 10        |
| 95  | Circulating miRNAs in Small Extracellular Vesicles Secreted by a Human Melanoma Xenograft in Mouse Brains. <i>Cancers</i> , 2020, 12, 1635.   | 1.7 | 9         |
| 96  | Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line. <i>British Journal of Cancer</i> , 1990, 61, 377-381.   | 2.9 | 8         |
| 97  | IL-2 reverses the inhibition of cytotoxic T-cell responses induced by 5-(3,3 $\beta$ ) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 507 Td (dm<br>Immunopharmacology, 1990, 12, 831-840.                           | 1.1 | 8         |
| 98  | Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL). <i>Cancer Immunology, Immunotherapy</i> , 1995, 41, 375-383.                  | 2.0 | 8         |
| 99  | Levels of expression of hRPB11, a core subassembly subunit of human RNA polymerase II, affect doxorubicin sensitivity and cellular differentiation. <i>FEBS Letters</i> , 1998, 427, 241-246.                     | 1.3 | 8         |
| 100 | In vitro and in vivo inhibition of SK-N-MC neuroblastoma growth using cyclic nucleotide phosphodiesterase inhibitors. <i>Journal of Neuro-Oncology</i> , 2001, 51, 25-31.   | 1.4 | 6         |
| 101 | Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. <i>International Journal of Oncology</i> , 2005, 26, 415.           | 1.4 | 6         |
| 102 | Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 316-326.  | 1.6 | 5         |
| 103 | Human placenta-derived neurospheres are susceptible to transformation after extensive in vitro expansion. <i>Stem Cell Research and Therapy</i> , 2014, 5, 55.  | 2.4 | 5         |
| 104 | Hybrid Self-Assembling Nanoparticles Encapsulating Zoledronic Acid: A Strategy for Fostering Their Clinical Use. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5138.                             | 1.8 | 5         |
| 105 | N-methylformamide induces changes on adhesive properties and lung-colonizing potential of M14 melanoma cells. <i>British Journal of Cancer</i> , 1998, 77, 210-215.   | 2.9 | 4         |
| 106 | Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 71. | 3.5 | 3         |
| 107 | Xenograft as In Vivo Experimental Model. <i>Methods in Molecular Biology</i> , 2018, 1692, 97-105.  | 0.4 | 3         |
| 108 | Pharmacological purging of syngeneic bone marrow ex vivo: Effect of treatment with doxorubicin and lonidamine on normal and leukaemic cells of mice. <i>European Journal of Cancer</i> , 1992, 28, 1633-1636.     | 1.3 | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Harnessing Omics Approaches on Advanced Preclinical Models to Discovery Novel Therapeutic Targets for the Treatment of Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1830.   | 1.7 | 2         |
| 110 | 441 POSTER The G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 138-139.                             | 2.2 | 1         |
| 111 | The role of mouse models in translational cancer research: present and future directions. <i>Translational Medicine Reports</i> , 2017, 1, .  | 0.8 | 1         |
| 112 | 334 POSTER Combination of c-myc and bcl-2 antisense oligonucleotides with docetaxel is highly effective in vitro and in vivo on hormone-refractory prostate cancer. <i>European Journal of Cancer, Supplement</i> , 2006, 4, 104. | 2.2 | 0         |
| 113 | Evidence for G-quadruplex in the promoter of VEGFR-2 and its targeting to inhibit tumor angiogenesis. <i>Nucleic Acids Research</i> , 2014, 42, 14083-14083.  | 6.5 | 0         |
| 114 | Stealth liposomes for the delivery of zoledronic acid into tumors enhance the anticancer activity of the drug. <i>Translational Medicine Reports</i> , 2017, 1, .   | 0.8 | 0         |
| 115 | Abstract 4237: Drug-releasing mesenchymal cells strongly suppress B16 lung metastasis in a syngeneic murine model. , 2015, , .  |     | 0         |
| 116 | Abstract 266: The G-quadruplex ligand EMICORON potentiates the antitumor efficacy of chemotherapy on colon cancer experimental models. , 2016, , .  |     | 0         |